Abstract:Abstract Prostate cancer (PCa) is the second leading cause of cancer-related deaths in males after lung cancer in the USA. Under normal conditions, the essential role of androgen through the androgen receptor (AR) is to support prostate epithelial cell growth, functional differentiation and survival. However, the androgen and AR-mediated signaling pathways can also promote genesis, progression and metastasis of prostate cancer. Thus, androgen deprivation or abrogation of the AR signaling remains the first-line treatment for human advanced prostate cancer. Unfortunately, these prostate cancers develop resistance to these therapies and progress to androgen-independent or castration-resistant prostate cancer (CRPC) with an average latency period of 18 months. Docetaxel chemotherapy and newly developed androgen synthesis blocker or AR signaling inhibitors have been demonstrated to be efficacious against CRPC. However, the median increase in survival was only four to five months. Thus, identification of molecular targets contributing to the initiation and progression of CRPC is a critical step to develop effective mechanism-based prostate cancer therapies. Recent studies provided compelling genetic evidence that Pten deletion, the most frequent genetic alterations identified in 70% of human advanced prostate cancers, promotes PCa progression to CRPC in preclinical mouse models. To understand the molecular mechanisms underlying Pten deletion-driven CRPC, we established an AR-positive prostate cancer cell line derived from an aggressive prostate tumor developed in a genetic mouse model carrying deletion of Pten only in prostate epithelium. Our initial characterization studies show that these cancer cells proliferated and grew well in an anchorage-independent growth assay either in the absence of androgen or genetic depletion of AR in vitro. In support of this notion, we found that these cancer cells formed tumors in female NOD/SCID IL2RG null mice. Interestingly, the tumors grow faster and larger in female NOD/SCID IL2RG null mice than in their male counterparts. These observations promoted us to further examine the role of estrogen in the development of CRPC. Genetic and pharmacologic studies suggested that estrogen, through its receptor alpha (ERα)-FOXA1-mediated signaling pathway, increased cancer cell proliferation in vitro and promoted prostate tumor development in xenografts in female SCID mice. Furthermore, we found that these cancer cells display features of epithelial-mesenchymal transition (EMT) as characterized by the loss of E-cadherin and CK8 coupled with an increase in N-cadherin, vimentin, and twist expression. Collectively, our data suggest that (ERα)-FOXA1-mediated signaling pathway and EMT play an important role in Pten deficiency-driven CRPC. Thus, targeting these signaling pathways might be a novel approach to complement current therapies of CRPC. Citation Format: Fengxia Wu, Lei Wang, Hua Xiong, Li-Ju Chang, Tao Lin, Junxuan Lu, Yibin Deng. Role of estrogen and epithelial-mesenchymal-transition in Pten deletion-driven castration-resistant prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3028. doi:10.1158/1538-7445.AM2013-3028 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.

TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer

Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes.

Supplementary Information from &Lt;i>tmprss2-Erg</i> Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in <i>pten</i> and &Lt;i>tp53</i>-Mutated Prostate Cancer

TMPRSS2-ERG Promotes the Initiation of Prostate Cancer by Suppressing Oncogene-Induced Senescence

Oncogenic ERG Represses PI3K Signaling Through Downregulation of IRS2.

ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming

Abstract 7077: The oncogenic transcription factor ERG has distinct roles and signaling in different prostate cancer cell types

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion

Overexpression of Truncated ERG from TMPRSS2-ERG Fusion and Prostate Cancer Development

ERG activates a stem-like proliferation-differentiation program in prostate epithelial cells with mixed basal-luminal identity

Abstract 1246: Erg-driven prostate cancer emerges from a basal subset of cells with luminal transcriptomic features

Inactivation of AR/TMPRSS2-ERG/Wnt Signaling Networks Attenuates the Aggressive Behavior of Prostate Cancer Cells

MP70-11 REVERSE OF DOCETAXEL RESISTANCE IN PROSTATE CANCER VIA NOTCH SIGNALING INHIBITION

The Germ Cell Gene TDRD1 As an ERG Target Gene and a Novel Prostate Cancer Biomarker

Association of Germline Genetic Variants with TMPRSS2-ERG Fusion Status in Prostate Cancer.

MP70-10 ASSOCIATION OF SINGLE NUCLEOTIDE POLYMORPHISMS WITH ERG FUSION STATUS IN PROSTATE CANCER

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

Abstract 3028: Role of Estrogen and Epithelial-Mesenchymal-transition in Pten Deletion-Driven Castration-Resistant Prostate Cancer.

TMPRSS2:ERG Gene Fusion Might Predict Resistance to PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer

MP90-16 THE ROLE OF PARP2 IN PROSTATE CANCER GROWTH AND PROGRESSION

Abstract 5878: ZNF397 loss triggers TET2-driven epigenetic rewiring, lineage plasticity, and AR-targeted therapy resistance